Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors

J Clin Oncol. 2022 Aug 10;40(23):2609-2611. doi: 10.1200/JCO.22.00562. Epub 2022 Jun 28.

Authors

Kathryn C Arbour^{1

2}, Piro Lito^{1

2

3}

Affiliations

¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
² Department of Medicine, Weill Cornell Medical College, New York, NY.
³ Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer, New York, NY.

PMID: 35763705
DOI: 10.1200/JCO.22.00562

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Cell Line, Tumor
Humans
Lung Neoplasms*
Mutation
Proto-Oncogene Proteins p21(ras)* / genetics

Substances

KRAS protein, human
Proto-Oncogene Proteins p21(ras)